Noninvasive prenatal diagnosis of congenital factor XIII deficiency in Iran

Blood Coagul Fibrinolysis. 2022 Apr 1;33(3):167-170. doi: 10.1097/MBC.0000000000001121. Epub 2022 Jan 3.

Abstract

Congenital factor (F) XIII deficiency is a rare coagulation factor deficiency that is inherited in an autosomal recessive manner. FXIII deficiency presents various clinical manifestations, such as intracranial hemorrhage (ICH), which is the most common cause of morbidity and mortality. As ICH can occur in the neonatal period, prenatal diagnosis (PND) is an effective way to reduce neonatal ICH and its associated fatal consequences. In this study, we investigated a noninvasive prenatal diagnosis (NIPD) method, cell-free fetal DNA (cffDNA), for PND in FXIII deficiency. This study was conducted on seven pregnant women in the first trimester. After extraction of cffDNA from maternal plasma, PCR-restriction fragment length polymorphism (PCR-RFLP) was performed to find the underlying F13A gene mutations previously identified in the family members. PCR-RFLP was also performed on postnatal DNA samples. Sanger sequencing was performed to confirm the results. Four cases were heterozygous for F13A gene mutations, whereas three were unaffected. PCR- RFLP results for cffDNA and postnatal DNA samples were identical, and Sanger sequencing confirmed the results. cffDNA is a noninvasive and effective method for PND in congenital FXIII deficiency.

MeSH terms

  • Factor XIII / genetics
  • Factor XIII Deficiency* / diagnosis
  • Factor XIII Deficiency* / genetics
  • Female
  • Heterozygote
  • Humans
  • Infant, Newborn
  • Intracranial Hemorrhages
  • Iran
  • Noninvasive Prenatal Testing*
  • Pregnancy
  • Prenatal Diagnosis

Substances

  • Factor XIII